Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors

α-Glucosidase inhibitors with a chlorinated phthalimide or a thiophthalimide skeleton, derived from thalidomide, were found to possess liver X receptor (LXR) antagonistic activity. Novel LXR antagonists with a 2′-substituted phenylphthalimide skeleton were obtained by structural development of glucosidase inhibitors derived from thalidomide.

Novel LXR antagonists with a 2′-substituted phenylphthalimide skeleton were obtained by structural development of glucosidase inhibitors derived from thalidomide.Figure optionsDownload as PowerPoint slide